Cerity Partners LLC increased its position in Integer Holdings Corporation by 344.2% during the third quarter, acquiring an additional 91,797 shares to bring its total holdings to 118,468 shares. By quarter end, Cerity Partners held 0.34% of Integer’s outstanding stock, valued at $12.24 million based on the latest SEC filing. This dramatic build indicates growing confidence among wealth-management firms in Integer’s advanced medical-device manufacturing capabilities.

Several other institutional investors shifted their exposure to Integer during the same period. North Growth Management lifted its stake by 5.1%, adding 5,000 shares to reach 103,000 shares. Global Retirement Partners expanded its tiny position by 293.8%, acquiring 238 additional shares to total 319. At the same time, Salomon & Ludwin initiated a new position worth $26,000, while Trust Point Inc. increased its holding by 11.9%, buying 505 shares. Congress Asset Management also grew its block by 8.9%, adding 47,480 shares and bringing its total to 578,287 shares—about 5.8% of total institutional ownership. Hedge funds and institutions now control over 99% of the company’s shares.

Wall Street sentiment has shifted toward moderation. Four firms maintain Buy ratings on Integer, while six have downgraded to Hold and one to Sell, resulting in an average recommendation of Hold. Notably, Bank of America, Argus and Wells Fargo all moved to neutral or equal-weight views during late October, revising their outlooks downward by 15%–40% on concerns around guidance execution and competitive pressure in drug-delivery markets. The consensus earnings forecast for fiscal 2025 stands at approximately 6.3 earnings per share.

In late October, CEO Payman Khales purchased 3,127 shares, boosting his direct stake by nearly 16%, while Vice President Tommy P. Thomas sold 884 shares in mid-November, reducing his holding by nearly 20%. Over the past 90 days, insiders collectively acquired 5,843 shares valued at $385,000, bringing total insider ownership to 2.16%. Concurrently, Integer’s board authorized a $200 million share-repurchase plan, permitting the company to buy back up to 8.3% of outstanding shares, underscoring management’s belief that the stock remains undervalued.